로딩 중…
StockDiggingStockDigging

KOREAN DRUG CO., LTD.

014570· KOSDAQ
₩3,350-1.18%
2026-06-19

Price Chart

KOREAN DRUG CO., LTD.-31.91%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap36.85B KRW
Revenue62.76B KRW
Net Income2.21B KRW
Total Assets96.39B KRW
Net Assets82.31B KRW
Employees172
Value
P/E16.66x
P/B0.45x
PEG0.33x
P/S0.59x
EV/EBITDA12.14x
FCF Yield34.34%
Profitability
ROE2.69%
ROA2.29%
Op. Margin3.60%
Revenue Growth1.92%
Earnings Growth49.88%
Financial Health
Debt Ratio17.12%
Total Debt0 KRW
FCF12.65B KRW
Cash9.40B KRW
Current Ratio6.63x
Net Debt/EBITDA-4.16x
Dividend
Div. Yield5.31%
Div. Growth12.50%
Performance
1Y Return-31.91%
1M Return-10.19%
From 52W High-35.20%
1Y MDD-37.29%
Trading
Volume7,362 shares
Foreign Own.3.04%
Per Share
EPS628 KRW
BPS7,604 KRW

Company Info

CEO 박해룡, 박상훈 (각자대표)
Employees 172
Founded 1980
HQ 경기도 이천시, KR

Koryo Pharm, established in 1980, manufactures and sells pharmaceuticals, listing on the KOSDAQ market in 2000. The company produces and distributes over-the-counter drugs, including Haben, a leading cold medicine in Korea, along with professional pharmaceuticals for central nervous system diseases such as dementia and epilepsy. Committed to public health, it conducts research and development for new drugs and generics, with its R&D capabilities recognized through patent applications and technology certifications. Koryo Pharm is headquartered in Icheon, Gyeonggi-do.